A Phase II Study of Nilotinib (AMN107) In TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral or Chronically Sun Damaged Melanoma

Trial Profile

A Phase II Study of Nilotinib (AMN107) In TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral or Chronically Sun Damaged Melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2016

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Sep 2016.
    • 19 Jan 2016 Planned End Date changed from 1 Feb 2015 to 1 Jun 2016, according to ClinicalTrials.gov record.
    • 30 Sep 2014 Status changed from active, no longer recruiting to completed, as reported at the 39th European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top